BioCardia (BCDA) Tax Provisions (2024 - 2025)
BioCardia's (BCDA) quarterly Tax Provisions came in at $1.4 million in Q4 2025, up 7.69% year-over-year from $1.3 million in Q4 2024, and up 7.69% quarter-over-quarter from $1.3 million in Q4 2024.
Powered by 
Analysis
BioCardia (BCDA) Tax Provisions (2024 - 2025) Analysis & Trends
BioCardia (BCDA) has reported Tax Provisions for 2 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Tax Provisions rose 7.69% year-over-year to $1.4 million in Q4 2025; TTM through Dec 2025 was $1.4 million, a 7.69% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 7.69% from the prior year.
- Tax Provisions was $1.4 million for Q4 2025 at BioCardia, up from $1.3 million in the prior quarter.
- Over five years, Tax Provisions peaked at $1.4 million in Q4 2025 and troughed at $1.3 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 11.31 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | 1.00 Mn |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -1.40 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -22.30 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 1.84 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 3.14 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | - |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | - |